By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement.
Cookie Disclaimer
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the app and the website, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide in the Cookie Settings which categories you would like to permit. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Statement.
Cookie Disclaimer
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., setting the language).
These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.
{"analytics":"targeting","share":"targeting"}
Disclaimer
Publication of Merck KGaA, Darmstadt, Germany.
In the United States and Canada the subsidiaries of
Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.
Schistosomiasis is one of the most prevalent parasitic infections in Africa, placing a significant burden on public health and local economies. Access to schistosomiasis innovation is the next frontier to reach the elimination of this disease. In the ISNTD Connect webinar we talked about our collaborative efforts to beat schistosomiasis.
On the 28th of January 2021 WHO launched its new NTD Roadmap 2030! We stay committed to actively support the efforts of the global elimination of NTDs, such as schistosomiasis.
Bilharzia Storytelling Lab
We hosted Bilharzia Storytelling Lab in Kenya. It offered Kenyan community leaders and storytellers the opportunity to envision new ways of accessible and tailored disease information.
To bolster Rwanda’s plan to end schistosomiasis by 2024, we will provide Rwanda, in partnership with The END Fund, with 8 million additional tablets of the standard medication for the treatment of schistosomiasis per year. The tablets are needed for treating adults endangered by schistosomiasis and will complement our annual donation for the treatment of school-aged children.
